



Do you or your child have a diagnosis of schizophrenia?



The CN012-0020 Study is researching a study drug called KarXT (xanomeline-trospium chloride). The goal of this study is to find out how safe KarXT is and how well it may work to help teenagers who have schizophrenia.

To participate in this study, participants must:

- Be 13–17 years of age
- Be diagnosed with schizophrenia
- Be willing to discontinue their current schizophrenia medication(s) during the study, which will be done under the care of a doctor

There are additional eligibility criteria, which a study doctor can explain to you.

Participants who complete the CN012-0020 Study will be eligible to enroll into a 52-week open-label extension study, during which they will receive KarXT every day and go to regular study visits.

For more information about the CN012-0020 Study, ask your or your child's doctor or visit [BMSClinicalTrials.com/us/en/clinical-trials/NCT07288567](https://www.bmsclinicaltrials.com/us/en/clinical-trials/NCT07288567). You may also reach out to a nearby research team with the contact information here.

Study coordinator name: _____

Study site address: _____

Study site phone number: _____